Your browser doesn't support javascript.
The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice.
Jiang, Xiaoliang; Li, Huadong; Liu, Yong; Bao, Linlin; Zhan, Lingjun; Gao, Hong; Deng, Wei; Xue, Jing; Liu, Jiangning; Liu, Xing; Li, Junli; Wang, Jie; Wu, Shuang; Yan, Mingzhe; Luo, Wei; Jose, Pedro A; Qin, Chuan; Yang, Xiuhong; Zhang, Dingyu; Yang, Zhiwei.
  • Jiang X; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
  • Li H; Jinyintan Hospital, Wuhan, China, Dongxihu District, Wuhan, 430023, People's Republic of China.
  • Liu Y; Department of Orthopedics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.
  • Bao L; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
  • Zhan L; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
  • Gao H; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
  • Deng W; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
  • Xue J; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
  • Liu J; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
  • Liu X; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
  • Li J; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
  • Wang J; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
  • Wu S; Jinyintan Hospital, Wuhan, China, Dongxihu District, Wuhan, 430023, People's Republic of China.
  • Yan M; Jinyintan Hospital, Wuhan, China, Dongxihu District, Wuhan, 430023, People's Republic of China.
  • Luo W; Department of Clinical Laboratory, General Hospital of Tianjin Medical University, No.154, Anshan Road, Heping District, Tianjin, 300052, People's Republic of China.
  • Jose PA; Division of Renal Diseases and Hypertension, Department of Medicine, and Department of Pharmacology/Physiology, The George Washington University School of Medicine and Health Sciences, Washington, DC, 20052, USA.
  • Qin C; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
  • Yang X; Department of Physiology, School of Basic Medical Sciences, North China University of Science and Technology, 57 Jianshe South Rd, Tangshan City, Hebei, 063000, People's Republic of China.
  • Zhang D; Jinyintan Hospital, Wuhan, China, Dongxihu District, Wuhan, 430023, People's Republic of China.
  • Yang Z; Key Laboratory of Human Disease Comparative Medicine Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Co
J Cardiovasc Transl Res ; 15(1): 38-48, 2022 02.
Article in English | MEDLINE | ID: covidwho-1594479
ABSTRACT
Angiotensin-converting enzyme 2 (ACE2) is required for the cellular entry of the severe acute respiratory syndrome coronavirus 2. ACE2, via the Ang-(1-7)-Mas-R axis, is part of the antihypertensive and cardioprotective effects of the renin-angiotensin system. We studied hospitalized COVID-19 patients with hypertension and hypertensive human(h) ACE2 transgenic mice to determine the outcome of COVID-19 with or without AT1 receptor (AT1R) blocker treatment. The severity of the illness and the levels of serum cardiac biomarkers (CK, CK-BM, cTnI), as well as the inflammation markers (IL-1, IL-6, CRP), were lesser in hypertensive COVID-19 patients treated with AT1R blockers than those treated with other antihypertensive drugs. Hypertensive hACE2 transgenic mice, pretreated with AT1R blocker, had increased ACE2 expression and SARS-CoV-2 in the kidney and heart, 1 day post-infection. We conclude that those hypertensive patients treated with AT1R blocker may be at higher risk for SARS-CoV-2 infection. However, AT1R blockers had no effect on the severity of the illness but instead may have protected COVID-19 patients from heart injury, via the ACE2-angiotensin1-7-Mas receptor axis.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hypertension Topics: Long Covid Limits: Animals / Humans Language: English Journal: J Cardiovasc Transl Res Journal subject: Vascular Diseases / Cardiology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hypertension Topics: Long Covid Limits: Animals / Humans Language: English Journal: J Cardiovasc Transl Res Journal subject: Vascular Diseases / Cardiology Year: 2022 Document Type: Article